Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 2/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10130728 | 0.91 | CHRNA7 (0.50) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL10168581 | 0.82 | CHRNA7 (0.34) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL10254882 | 0.76 | — | — | |
| SCHEMBL12205477 | 0.73 | CHRNA7 (0.43) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL26537774 | 0.71 | CHRNA7 (0.32) | CHRNA7 | |
| SCHEMBL24815577 | 0.71 | CHRNA7 (0.42) | CHRNA7KDM4EALDH1A1MAPTPKM | |
| SCHEMBL104677 | 0.71 | — | — | |
| SCHEMBL57304 | 0.71 | — | — | |
| SCHEMBL24496310 | 0.71 | CHRNA7 (0.42) | CHRNA7HRH3KDM4EALDH1A1MAPT | |
| SCHEMBL840178 | 0.71 | CHRNA7 (0.42) | CHRNA7HRH3KDM4EALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912723-B2 | KRAS modulators and uses thereof | QUANTA THERAPEUTICS, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2022170974-A1 | TRICYCLIC DERIVATIVES USEFUL AS PARP7 INHIBITORS | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2022-08-18 | — | — | WO | disclosed |
| WO-2021012049-A1 | SUBSTITUTED 2-MORPHOLINOPYRIDINE DERIVATIVES AS ATR KINASE INHIBITORS | REPARE THERAPEUTICS INC. (CA) | 2021-01-28 | — | — | WO | disclosed |
| WO-2020160192-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374042-A1 | KRAS MODULATORS AND USES THEREOF | KRAS, NRAS, HRAS | CHRNA7 4728/4885HRH3 2573/4885KDM4E 4616/4885 |
| US-11912723-B2 | KRAS modulators and uses thereof | KRAS, NRAS, HRAS | CHRNA7 4728/4885HRH3 2573/4885KDM4E 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.